China Cosmetics Update: NMPA Registration Backlog Reaches 35,000+ — What Brands Must Know
As of Q4 2024, the National Medical Products Administration (国家药品监督管理局, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) is managing a reported backlog of over 35,000 cosmetics registration applications, with average processing times for imported general cosmetics stretching to 14–18 months — more than double the 6–8 months common in 2021. This bottleneck follows China’s comprehensive regulatory overhaul under the Cosmetic Supervision and Administration Regulation (化妆品监督管理条例, CSAR, huàzhuāngpǐn jiāndū guǎnlǐ tiáolì), which took full effect in May 2021 and introduced stricter safety assessment, ingredient disclosure, and efficacy claim requirements. For foreign beauty brands eyeing China’s $80 billion cosmetics market — the world’s second-largest — understanding this backlog is now critical to market entry timing, budget planning, and product portfolio strategy.
What Caused the NMPA Backlog?
The backlog is not a single-event crisis but the result of converging regulatory, administrative, and market forces that have built up over three years. The CSAR replaced a fragmented system that had governed cosmetics since the 1990s, introducing a two-tier classification system: special-use cosmetics (特殊化妆品, tèshū huàzhuāngpǐn) — covering sunscreen, whitening, anti-hair loss, and colorants — require full NMPA registration; general cosmetics (普通化妆品, pǔtōng huàzhuāngpǐn) — such as cleansers, moisturizers, and makeup — require filing with provincial authorities but still face review backlogs in practice.
Between 2021 and 2023, the NMPA received a cumulative 40% increase in new submissions as global brands rushed to comply with the new framework before transitional deadlines. However, the administration did not proportionally scale its review staff or digital infrastructure. Internal industry estimates suggest the NMPA’s cosmetics evaluation center has fewer than 200 full-time reviewers handling both new registrations and the re-evaluation of legacy products that must transition to the new system by 2025. This creates a structural bottleneck: even as the total submission queue grows, throughput capacity remains flat.
A further complication is safety assessment documentation. Under the CSAR, all cosmetic products must submit a complete safety assessment report (安全评估报告, ānquán pínggù bàogào) signed by a qualified safety assessor. China currently has fewer than 1,000 NMPA-certified safety assessors, compared to an estimated need of over 5,000 to clear the current pipeline. Brands that submitted incomplete or poorly formatted assessments face request-for-comment (RFC) cycles that add 3–6 months per application.
Impact on Foreign Cosmetic Brands Entering China
The backlog hits imported cosmetics disproportionately harder than domestic products. Foreign brands account for an estimated 70% of the pending submissions, largely because their applications require additional verification steps: notarized free-sale certificates from the country of origin, GMP compliance audits, and translation of all ingredient and safety documents into Chinese. Domestic brands, by contrast, often submit through provincial filing channels that process general cosmetics in 5–10 business days — a stark contrast to the 14–18 months for imported general cosmetics under NMPA review.
This disparity creates a real competitive disadvantage. Consider a typical timeline: an American indie skincare brand decides to enter China in early 2024. It prepares its registration dossier, submits to NMPA by June 2024, and expects approval by late 2025 — meaning it cannot sell a single unit on Tmall Global or Douyin until 2026. Meanwhile, a comparable domestic brand with a provincial filing can launch in Q1 2024. By the time the foreign brand’s product reaches shelves, two years of market momentum, trend cycles, and consumer loyalty have been lost.
The financial implications are significant. Brands that had planned to allocate 12–18 months from decision to first sale must now budget for 24–30 months. Holding inventory, paying retainers to China-based regulatory consulting firms, and maintaining legal entities (外商独资企业, WFOE, wàishāng dúzī qǐyè) during the wait can cost RMB 500,000–1,000,000 per year in carrying costs alone. For smaller brands, this can be a deal-breaker.
How the Backlog Is Being Addressed — and What to Expect
The NMPA has acknowledged the backlog and initiated several remediation measures since early 2023. First, it introduced a priority review pathway (优先审评, yōuxiān shěnpíng) for products with innovative ingredients, pediatric use, or that have been approved by a reference regulatory authority such as the US FDA, EU EMA, or Japan’s PMDA. In practice, less than 5% of submissions currently qualify for priority review, and the criteria remain narrow. However, brands that have obtained prior approvals from recognized authorities — for example, an FDA-cleared sunscreen formulation — should explicitly request priority status and document the approval trail.
Second, the NMPA has been expanding its digital submission platform, the Cosmetics Registration and Filing Information System (化妆品注册备案信息服务平台, CRFIS, huàzhuāngpǐn zhùcè bèi’àn xìnxī fúwù píngtái). As of mid-2024, the platform supports partial electronic submission for general cosmetics, reducing document handling time by an estimated 20%. However, special-use cosmetics still require hard-copy dossiers in many cases, and system outages have been reported during peak submission windows.
Third, the NMPA has encouraged brands to use its pre-submission consultation service (注册前咨询, zhùcè qián zīxún), which allows applicants to meet with reviewers for 30-minute slots to clarify documentation requirements before formal submission. Industry data suggests that brands using this service experience 35% fewer RFC cycles and reduce overall registration time by 3–5 months. This service is free but requires booking 4–6 weeks in advance and is available only in Beijing and Shanghai.
Looking ahead, the most significant near-term development is the 2025 transition deadline. All legacy cosmetic products registered before May 2021 must be fully re-registered under the CSAR by May 2025. As of late 2024, only about 40% of an estimated 80,000 legacy products have been transitioned — meaning a second wave of submissions will hit the NMPA in the first half of 2025, likely worsening the backlog before it improves. Foreign brands with legacy registrations should begin the transition process no later than Q1 2025 to avoid having their products delisted.
| Metric | Pre-CSAR (2019–2020) | Current (2024) | Δ Change |
|---|---|---|---|
| Avg. registration time — imported general cosmetics | 6–8 months | 14–18 months | +100% to +125% |
| Avg. registration time — imported special-use cosmetics | 10–14 months | 20–26 months | +85% to +100% |
| NMPA-certified safety assessors (estimated) | ~300 | ~950 | +217% |
| Estimated submissions per year | ~18,000 | ~25,000 | +39% |
| Legacy products pending transition (by May 2025) | N/A | ~48,000 | N/A |
| Priority review approval rate | N/A | <5% | N/A |
Sources: NMPA public announcements, China Association of Cosmetics Industry data, internal CG360 estimates.
Strategic Takeaways for Beauty Brands
Given the current state of the NMPA registration backlog, cosmetic brands need to adjust their China market entry plans with realistic timelines and alternative pathways. The most important takeaway is that the old assumption of a 12-month window from decision to first sale is no longer valid for imported products going through standard registration. Brands should budget for 24–30 months and consider using cross-border e-commerce (跨境电子商务, kuàjìng diànzǐ shāngwù) channels — such as Tmall Global, JD Worldwide, or Douyin Global — as a bridge strategy that allows sales without full NMPA registration, provided products use the bonded warehouse model (1210 customs code).
For brands that are determined to pursue full registration, the pre-submission consultation service is the single highest-ROI action available. Investing in a high-quality safety assessment report drafted by an NMPA-certified assessor — costing RMB 30,000–80,000 depending on product complexity — can reduce RFC cycles and shave months off the timeline. Similarly, appointing a domestic responsible person (境内责任人, jìngnèi zérènrén) with proven experience in CSAR compliance can prevent basic filing errors that trigger delayed reviews.
Finally, brands should monitor the NMPA’s upcoming implementation rules for the 2025 transition wave. The administration has signaled that it may introduce a fast-track renewal process for legacy products with no formulation changes, but no formal policy has been released. Engaging with industry associations like the China Association of Cosmetics Industry (中国化妆品行业协会, Zhōngguó huàzhuāngpǐn hángyè xiéhuì) can provide early access to draft regulations and pilot programs that may offer temporary relief.
NEXT STEPS
- Audit your product portfolio for CSAR readiness: Review your current or planned China product lineup against the special-use vs. general cosmetics classification. Determine which products require full NMPA registration and which can use provincial filing. Read our Cosmetic Classification Guide for China.
- Evaluate cross-border e-commerce as a bridge strategy: If your brand has not yet entered China, consider launching through Tmall Global or Douyin Global while NMPA registration is in progress. This allows revenue generation and consumer testing during the 18–24 month wait. Compare cross-border vs. general trade entry options.
- Book an NMPA pre-submission consultation: If you are preparing a registration dossier, schedule a pre-submission consultation with the NMPA at least 6 weeks before your planned submission date. Prepare a dossier gap analysis in advance to maximize the session. See our pre-submission consultation preparation checklist.
— China Gateway 360 —
Remote China market entry support, built around execution.
